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Objectives: This study sought to examine the relationship between temperature at
reperfusion and infarct size.
Background: Hypothermia consistently reduces infarct size when administered prior
to reperfusion in animal studies, however, clinical results have been inconsistent.
Methods:We performed a patient-level pooled analysis from six randomized control
trials of endovascular cooling during primary percutaneous coronary intervention (PCI)
for ST-segment elevationmyocardial infarction (STEMI) in 629patients inwhich infarct
sizewas assessedwithin 1month after randomization by either single-photon emission
computed tomography (SPECT) or cardiac magnetic resonance imaging (cMR).
Results: In anterior infarct patients, after controlling for variability between studies,
mean infarct size in controls was 21.3 (95%CI 17.4-25.3) and in patients with
hypothermia <35°C it was 14.8 (95%CI 10.1-19.6), which was a statistically significant
absolute reduction of 6.5%, or a 30% relative reduction in infarct size (P = 0.03). There
was no significant difference in infarct size in anterior ≥35°C, or inferior infarct
patients. There was no difference in the incidence of death, ventricular arrhythmias, or
re-infarction due to stent thrombosis between hypothermia and control patients.
Conclusions: The present study, drawn from a patient-level pooled analysis of six
randomized trials of endovascular cooling during primary PCI in STEMI, showed a
significant reduction in infarct size in patients with anterior STEMIwhowere cooled to
<35°C at the time of reperfusion. The results support the need for trials in patientswith
anterior STEMI using more powerful cooling devices to optimize the delivery of
hypothermia prior to reperfusion.
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1 | INTRODUCTION
Prompt reperfusion remains the most effective treatment to date for
preservation of myocardium following acute coronary occlusion.
However, large infarctions still occur despite timely reperfusion, due to
reperfusion injury.1 Numerous treatments have been studied to reduce
reperfusion injury,with little success todate.2Hypothermiahasshownthe
ability to consistently reduce infarct size when administered prior to
reperfusion in preclinical studies.3–6 Results from clinical trials, however,
havebeen inconsistent.7–11Onemajordifferencebetweenpreclinical and
clinical trials is the lack of achievement of an effective degree of cooling
prior to reperfusion in patients, as occurred in experimental studies.12 In
the clinical trials to date, a suggestion has been made that patients that
achieved a core body temperature less than 35°C prior to reperfusion
showed smaller infarcts, at least in those with anterior infarction.8
However, sample sizes were not sufficient to confirm these findings in
individual clinical studies.We therefore performed a patient-level pooled
analysis from six randomized trials of endovascular cooling during primary
PCI for STEMI in 629 patients, to examine the relationship between
temperature at reperfusion and infarct size.
2 | METHODS
2.1 | Study population
This study is a patient-level pooled analysis of six hypothermia trials
using endovascular cooling in which infarct size (IS) was assessed by
either cardiac magnetic resonance (cMR) or technetium (Tc)-99m
sestamibi single-photon emission computed tomography (SPECT)
within 1 month after reperfusion at a core laboratory. Adverse events
were followed through 30 days.
2.2 | Studies and characteristics
The randomized trials included in the pooled analysis were: COOL MI
Pilot,8 in which patients presenting with anterior or inferior STEMI
within 6 h of symptom onset were randomized to primary PCI and
cooling to a target temperature of 33°C using an endovascular cooling
catheter (Radiant Medical Inc., Redwood City, CA) versus PCI alone.
Target temperature was maintained for 3 h post PCI; COOL-MI
Pivotal,7 in which patients presenting with anterior or inferior STEMI
within 6 h of symptom onset were randomized to primary PCI and
cooling to a target temperature of 33°C using an endovascular cooling
catheter (Radiant Medical Inc.) versus PCI alone. Target temperature
was maintained for 3 h post PCI; COOL MI II, in which patients
presenting with anterior STEMI within 6 h of symptom onset were
randomized to primary PCI and cooling to a target temperature of 32°C
using an endovascular cooling catheter (Radiant Medical Inc.) versus
PCI alone. Target temperature was maintained for 3 h post PCI; ICE-
IT,9 in which patients presenting with anterior or inferior STEMI within
6 h of symptom onset were randomized to primary PCI and cooling to a
target temperature of 33°C using an endovascular cooling catheter
(Innercool Therapies Inc., San Diego, CA) versus PCI alone. Target
temperature was maintained for 6 h post PCI; RAPID MI-ICE,10 in
which patients presenting with anterior or inferior STEMI within 6 h of
symptom onset were randomized to primary PCI and cooling to a
target temperature of 33°C using an endovascular cooling catheter
(Innercool Therapies Inc.) and cold saline infusion versus PCI alone.
Target temperature was maintained for 3 h post PCI; and CHILL-MI,11
in which patients presenting with anterior or inferior STEMI within 6 h
of symptom onset were randomized to primary PCI and cooling to a
target temperature of 33°C using an endovascular cooling catheter
(Innercool Therapies Inc.) and cold saline infusion versus PCI alone.
Target temperature was maintained for 1 h post PCI.
Data was available for each individual patient included. The data
analysis included the patients with available infarct size and
temperature at PCI for cooled patients, and excluded patients with
prior-MI. In order tomore precisely estimate the effect of hypothermia
on infarct size, only patients that received cooling (per-protocol
patients) were included. This analysis further refined the assessment of
hypothermia trials by categorizing hypothermia patients using
temperature at PCI (<35°C and ≥35°) for assessment of hypothermia
and infarct size.
2.3 | Statistical analyses
For descriptive analyses, values are presented as mean and standard
deviation or median and 25th and 75th quartile depending on a test of
normality. Comparison of categorical variables were done with chi-
square tests or Fisher's exact tests if number of patients were fewer
than five. Continuous variables were compared with ANOVA or the
Wilcoxon rank sum test after examining for normality. Relationship
between infarct size and hypothermia was assessed through general-
ized linear models for infarct size that include the group term (Control,
<35°C, ≥35°C) as fixed effect and study (RAPID-MI-ICE, CHILL-MI,
COOL MI Pilot, COOL MI I, COOL MI II, ICE-IT) as a random effect to
account for potential heterogeneity across studies. Unadjusted and
adjusted means were calculated. Dunnett-Shu post-hoc test was
conducted for multiple comparisons comparing Control with <35°C or
Control with ≥35°C. No transformation or imputation was made for
infarct size. A sensitivity analysis was conducted using temperature
cutoffs at 34.5°C and 34.0°C for hypothermia patients with anterior
infarcts.
Separate multivariable models were fitted to evaluate the
potential effects of door to balloon time (<90min, ≥90min), ischemic
time (<4 h, ≥4 h), age (<65 years, ≥65 years), weight status (<25 BMI,
≥25 BMI) as fixed effects on relationship between infarct size and
group term using Type III tests. Effect modifications were considered
by adding a multiplicative interaction term between group term and
the modification factor. Subgroup analyses door to balloon time
(<90min, ≥90min), ischemic time (<4 h, ≥4 h), age (<65 years, ≥65
years), weight status (<25 BMI, ≥25 BMI), smoking (current smoker vs),
TIMI flow pre (0.1 vs 2.3) were conducted by using subsets of the data.
All statistical analyses were two-sided with P<0.05 considered
statistically significant and conducted using SAS 9.3 (SAS Institute,
North Carolina).
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3 | RESULTS
Description of the trials is presented in Table 1. Slightly less than half of
the patients included in this analysis presented with anterior infarcts.
Of the patients in the control group, 45% had anterior infarcts, of the
hypothermia <35°C group 44%, and of the hypothermia ≥35°C group,
44%. The baseline demographic and clinical characteristics for patients
with both anterior and inferior infarcts are presented in Table 2. The
majority of the patient populationweremale, older (>65 years old), had
a history of hypertension, and about half were smokers. In the
hypothermia ≥35°C patients, history of diabetes was more prevalent
(P = 0.03), and there was a higher proportion of current smokers
(P = 0.03). The same pattern of distribution was found in anterior only
and inferior only patients (data not shown).
Figures 1–3 present the distribution of infarct size by infarct
location.Mean andmedian infarct sizeswere smaller for patients in the
hypothermia <35°C group, in combined anterior and inferior, and
anterior infarct patients, but not in patients with inferior infarcts. In
combined anterior and inferior patients, mean infarct sizewas 14.4 (SD
14.9) in Controls, 13.8 (SD 14.1) in hypothermia ≥35°C, and 12.3 (SD
12.3) in hypothermia <35°C (Figure 1). In anterior patients, the same
pattern exists, where mean infarct size was 21.0 (SD 16.9) in Controls,
19.6 (SD 16.7) in hypothermia ≥35°C, and 15.3 (SD 15.2) in
hypothermia (<35°C) (Figure 2). Furthermore, there was a statistically
significant absolute difference of 5.77% (27% relative reduction) in
anterior infarct size between Control and patients who had a body
temperature below 35°C at time of PCI in a simple comparison that
excluded patients who did not reach 35°C (P = 0.02). Among inferior
infarct patients, therewas no significant difference between any of the
three groups (Figure 3).
Table 3 presents the unadjusted mean (arithmetic mean) and the
adjusted mean of infarct size for anterior, inferior, and all patients
(combined anterior and inferior) by group (Control, ≥35°C, <35°C)
after controlling for variability across the trials and multiple
comparisons. The results reflect a consistent pattern in all patients
and anterior patients, where mean infarct size of control was higher
than for hypothermia patients, and those patients who reached a body
temperature of <35°C at time of PCI had a smaller adjusted mean
infarct size than hypothermia patients who had a temperature of
≥35°C at time of PCI. Among all patients, infarct size was different by
group (P = 0.047) after accounting for study heterogeneity; specifi-
cally, there was a statistically significant relative reduction of 20%
(absolute adjusted mean infarct size of 15.7% vs 12.5%) between
Control and Hypothermia <35°C. Among anterior patients, the
relationship was even stronger. There was a marginal to significant
association between group and infarct size in both unadjusted and
adjusted models (P = 0.058, P = 0.030, respectively). In addition to a
statistically significant relative reduction of 27% observed in
TABLE 1 Study descriptions of study population
Infarct size location
Study Infarct size assessment Inferior N (%) Anterior N (%) All (N %)
ALL N (%) Control 171 (54.81) 141 (45.19) 312 (49.6)
N (%) Hypothermia ≥ 35°C 90 (56.25) 70 (43.75) 160 (25.4)
N (%) Hypothermia < 35°C 88 (56.05) 69 (43.95) 157 (25.0)
COOL-MI Pilot (2001) SPECT at 30 days N (%) Control 9 (52.94) 8 (47.06) 17 (51.52)
N (%) Hypothermia ≥ 35°C 4 (50) 4 (50) 8 (24.24)
N (%) Hypothermia < 35°C 4 (50) 4 (50) 8 (24.24)
COOL-MI 1 (2003) SPECT at 30 days N (%) Control 76 (56.3) 59 (43.7) 135 (50.19)
N (%) Hypothermia ≥ 35°C 43 (53.09) 38 (46.91) 81 (30.11)
N (%) Hypothermia < 35°C 37 (69.81) 16 (30.19) 53 (19.7)
ICE-IT (2004) SPECT at 30 days N (%) Control 58 (60.42) 38 (39.58) 96 (52.46)
N (%) Hypothermia ≥ 35°C 34 (62.96) 20 (37.04) 54 (29.51)
N (%) Hypothermia < 35°C 19 (57.58) 14 (42.42) 33 (18.03)
COOL-MI 2 (2006) SPECT at 30 days N (%) Control 0 (0) 8 (100) 8 (26.67)
N (%) Hypothermia ≥ 35°C 0 (0) 20 (100) 2 (6.67)
N (%) Hypothermia < 35°C 0 (0) 2 (100) 20 (66.67)
RAPID-MI-ICE (2009) CMR at 4 ± 2 days N (%) Control 2 (22.22) 7 (77.78) 9 (50)
N (%) Hypothermia ≥ 35°C 0 (0) 1 (100) 1 (5.56)
N (%) Hypothermia < 35°C 3 (37.5) 5 (62.5) 8 (44.44)
CHILL-MI (2013) CMR at 4 ± 2 days N (%) Control 26 (55.32) 21 (44.68) 47 (48.96)
N (%) Hypothermia ≥ 35°C 9 (64.29) 5 (35.71) 14 (14.58)
N (%) Hypothermia < 35°C 25 (71.43) 10 (28.57) 35 (36.46)
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unadjusted mean after controlling for multiple comparison, the
adjusted mean in controls was 21.3 (95%CI 17.4-25.3) and patients
with Hypothermia <35°C it was 14.8 (95%CI 10.1-19.6), which was an
absolute reduction of 6.5%, or a 30% relative reduction in adjusted
mean infarct size (P < 0.05) controlled for multiple comparison using all
data (Table 3). Other models examined showed that additional
covariates did not significantly effect relationship for infarct size and
group (data not shown). Sensitivity analyses using lower temperature
cutoffs for hypothermia groups (<34.5°C or <34°C) in anterior infarcts
showed the same pattern of reduction of infarct size with smaller
adjusted mean infarct size in the lower temperature group compared
to controls (Supplemental Figure S1).






N = 157 P-val*
Gender N (%) Female 69 (22.12) 29 (18.13) 38 (24.2) 0.403
N (%) Male 243 (77.88) 131 (81.88) 119 (75.8)
>65 years old N (%) No 226 (72.44) 123 (76.88) 116 (73.89) 0.582
N (%) Yes 86 (27.56) 37 (23.13) 41 (26.11)
Diabetes mellitus N (%) No 272 (87.74) 127 (79.38) 138 (87.9) 0.032
N (%) Yes 38 (12.26) 33 (20.63) 19 (12.1)
Hypertension N (%) No 189 (60.77) 96 (60) 84 (53.5) 0.3
N (%) Yes 122 (39.23) 64 (40) 73 (46.5)
Current smoker N (%) No 100 (41.32) 42 (36.21) 65 (52.85) 0.026
N (%) Yes 142 (58.68) 74 (63.79) 58 (47.15)
Prior stroke or transient ischemic
attack
N (%) No 307 (98.4) 156 (97.5) 154 (98.09) 0.808
N (%) Yes 5 (1.6) 4 (2.5) 3 (1.91)
TIMI Flow Grade—prior to PCI 0
or 1
N (%) No 76 (24.6) 41 (25.63) 42 (28) 0.736
N (%) Yes 233 (75.4) 119 (74.38) 108 (72)
TIMI Flow grade—post pci N (%) 0 1 (0.3) 2 (1.2) 0 (0) 0.389
N (%) 1 0 (0) 1 (0.6) 0 (0)
N (%) 2 17 (5.5) 10 (6.3) 7 (4.5)
N (%) 3 291 (93.3) 146 (91.3) 144 (91.7)
Door to balloon >90min N (%) No 182 (61.07) 81 (50.63) 89 (57.42) 0.098
N (%) Yes 116 (38.93) 79 (49.38) 66 (42.58)
Ischemic time >4 h N (%) No 199 (66.78) 92 (57.5) 103 (66.03) 0.122
N (%) Yes 99 (33.22) 68 (42.5) 53 (33.97)
Height (cm)a Mean (SD) 173.0 (9.3) 174.51 173.9 (9.6) 0.28
Weight (kg)b Mean (SD) 85.57 (15.8) 87.47 (17.3) 86.47 (16.2) 0.488
BMIc Mean (SD) 28.42 (4.3) 28.58 (4.7) 28.42 (5.1) 0.932
Onset to ER (min)d Mean (SD) 130.62
(90.3)
143.17 (97.7) 120.57 (77.2) 0.079
Cooling time (min)e Mean (SD) 14 (17.0) 26.2 (14.9)
Temperature at start of cooling
(degrees C)
Mean (SD) 36.27 (0.5) 35.77 (0.8)
Temperature at first balloon
(degrees C)
Mean (SD) 35.27 (3.4) 34.04 (0.6)
*The parametric P-value is calculated by ANOVA for numerical covariates and chi-square test for categorical covariates.
aData unavailable from 17 patients in Control, 8 patients in Hypothermia <35°C, 19 patients in Hypothermia >35°C.
bData unavailable from 5 patients in Control, 1 patient in Hypothermia <35°C, 2 patients in Hypothermia >35°C.
cData unavailable from 17 patients in Control, 8 patients in Hypothermia <35°C, 19 patients in Hypothermia >35°C.
dData unavailable from 1 patient in Control, 1 patient in Hypothermia <35°C.
eCooling time prior to PCI. Data unavailable from 1 patient in Hypothermia <35°C, 1 patient in Hypothermia >35°C.
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Table 4 presents interaction analyses that examine effect
modification by weight, ischemic time, door to balloon time, and
pre-TIMI flow using adjusted means among patients with anterior
infarcts with study as a random effect. Overall, we found no effect
modification in the factors examined. There was a consistent pattern
where adjusted mean of infarct size was smaller in patients reaching
<35°C than in Controls or patients who had a higher temperature at
time of PCI (Table 4).
Incidence of adverse events in Control versus Hypothermia
patients for all patients is reported in Table 5. There were no
statistically significant differences between Control and Hypothermia
patients for death (P = 0.46), re-infarction (P = 1.00), heart failure/
pulmonary edema (P = 0.72), ventricular tachycardia (P = 0.67), brady-
arrhythmias (P = 0.92), or bleeding (P = 0.59) (Table 5).
4 | DISCUSSION
The present study, drawn from a patient-level pooled analysis of six
randomized trials of endovascular cooling during primary PCI in STEMI,
showed a significant reduction in infarct size in patients with anterior
STEMI who were cooled to <35°C at the time of reperfusion. After
controlling for variability between studies, there was a clinically and
statistically significant absolute reduction of 6.5%, or a 30% relative
reduction in infarct size compared to Controls. The relationship
between hypothermia group and infarct size was not modified by
weight status, ischemic time, door to balloon time, or pre-TIMI flow.
These variables were thought pertinent to the outcomes of the study.
The ability of endovascular catheters to achieve sufficient cooling may
be affected by weight status. Ischemic time and door to balloon time,
particularly with significant delays due to the cooling procedure, may
affect the results. The mean difference in door to balloon time
between controls and hypothermia patients was 6min (control—
FIGURE 1 Distribution of infarct size by group in all anterior and
inferior patients. (Highest and lowest values are represented at the
ends; lines represent quartiles and median; mean is the red
diamond)
FIGURE 2 Distribution of infarct size by group in anterior
patients. (Highest and lowest values are represented at the ends;
lines represent quartiles and median; mean is the red diamond)
FIGURE 3 Distribution of infarct size by group in inferior
patients. (Highest and lowest values are represented at the ends;
lines represent quartiles and median; mean is the red diamond)
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86 ± 60min vs hypothermia—92 ± 49min, P = 0.20). Pre-TIMI flow
allows the assessment of treatment response in patients with
persistent occlusion versus spontaneous reperfusion prior to PCI.
The presence of collateral flow and cumulative disease burden may
also influence outcomes, however, this data was not available for
consideration. There was no difference in deaths, ventricular
arrhythmias, or re-infarction due to stent thrombosis between
hypothermia and control patients
Numerous strategies to reduce reperfusion injury have been
unsuccessful to date.2,13 Hypothermia has been shown to be an
effective therapy to help prevent reperfusion injury in preclinical
studies when administered prior to reperfusion, regardless of the
species tested.3–6 This has led to the assessment of hypothermia in
clinical trials as a means to reduce reperfusion injury in patients.
Challenges to overcome for inducing hypothermia in STEMI patients
included the ability to control shivering in awake patients,14 and
developing a means to rapidly reduce core body temperature in the
much larger thermal mass in patients compared to most experimental
models. The clinical studies included in this pooled analysis used
endovascular cooling to lower core body temperature, and all were
successful in controlling shivering using a combination of oral
buspirone, intravenous meperidine, and surface warming. The results
of these trials were mixed, and not as successful as was found in
experimental studies. In all of the clinical trials, there was no significant
difference in infarct size between hypothermia patients and controls.
Post-hoc analysis of one of the early endovascular cooling trials
(COOL-MI) suggested that patients with anterior STEMI who were
cooled to less than 35°C prior to reperfusion showed smaller infarct
size relative to controls, implying a dose response relationship.7
Preclinical studies have also reported a dose response whereby
moderate (32°C) therapeutic hypothermia showed a strong dose-
dependent infarct size reduction and favorable hemodynamic out-
comes versus mild (35°C) hypothermia.15 Our results support the
suggestion that patients with anterior STEMI who were cooled to less
than 35°C prior to reperfusion (mean temperature at PCI was 34°C)
had significantly smaller infarcts compared to controls, and to patients
TABLE 3 Unadjusted and adjusted mean* (95%CI) of Infarct Size
Model Control mean (95%CI) Hypothermia ≥35°C mean (95%CI) Hypothermia <35°C mean (95%CI) P-val
All
Unadjusted 14.4 (12.8-15.9) 13.8 (11.6-16.0) 12.3 (10.1-14.6) 0.343
Adjusted* 15.7 (11.8-19.7) 15.7 (11.4–20.0) 12.5 (8.3-16.6)** 0.047
Anterior
Unadjusted 21.0 (18.3-23.8) 19.6 (15.7-23.4) 15.3 (11.4-19.2)** 0.058
Adjusted* 21.3 (17.4-25.3) 20.4 (15.4-25.3) 14.8 (10.1-19.6)** 0.030
Inferior
Unadjusted 8.9 (7.4-10.3) 9.3 (7.3-11.3) 10.1 (8.0-12.1) 0.634
Adjusted* 9.4 (6.2-12.5) 10.1 (6.6-13.5) 9.8 (6.4-13.2) 0.833
*Adjusted by random effect of study.
**P < 0.05 compared to Control after post-hoc adjustment (Dunnett-Hsu).
TABLE 4 Adjusted mean (95%CI) of infarct size in subgroups* in anterior STEMI patients
Control Hypothermia ≥35°C Hypothermia <35°C Interaction P-val*
Weight 0.59
BMI ≤ 25 (n = 63) 21.8 (14.3-29.4) 25.2 (16.1-34.3) 13.3 (4.0-22.6)
BMI >25 (n = 203) 21.4 (18.2-24.5) 19.2 (14.5-24.0) 15.6 (10.9-20.3)
Ischemic Time 0.86
≤4 h (n = 174) 19.9 (15.7-24.2) 18.4 (12.8-24.0) 13.7 (8.6-18.8)
>4 h (97) 22.3 (15.6-29.0) 22.2 (14.5-30.0) 18.7 (10.5-26.9)
Door to balloon time 0.86
≤90min (n = 149) 21.4 (17.2-25.7) 19.9 (13.9-25.9) 14.9 (9.3-20.5)
>90min (n = 121) 19.4 (12.5-26.2) 20.1 (12.5-27.6) 14.9 (7.3-22.5)
Pre-TIMI flow 0.61
Pre-TIMI flow 0 or 1 (n = 196) 24.0 (20.8-27.1) 21.4 (16.7-26.1) 19.4 (14.2-24.6)
Pre-TIMI flow 2 or 3 (n = 76) 12.7 (6.1-19.3) 15.6 (8.3-23.0) 7.8 (0.7-14.9)
*Models are adjusted by random effect of study; interaction term consists of stratification factor and hypothermia treatment
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who were cooled to a temperature ≥ 35°C prior to reperfusion (mean
temperature 35.2°C). This relationship between lower temperature at
PCI and smaller infarct size was consistent and not affected by
ischemic time, door to balloon time, or pre-TIMI flow.
Hypothermia influences numerous mechanisms leading to cell
protection during ischemia and reperfusion,12 and has the unique
advantage of delivery to the ischemic bed in the absence of antegrade
flow, prior to reperfusion, due to conduction cooling from the blood
pool to the myocardium.3 In contrast, pharmaceutical agents can only
reach the ischemic territory after reperfusion, or potentially via
collateral blood flow. Preclinical studies have shown that induction of
cooling after reperfusion fails to reduce infarct size.16
There were no major safety issues with hypothermia compared to
the normothermia control patients. There was no difference in deaths,
ventricular arrhythmias, or re-infarction due to stent thrombosis. The
6.5% absolute infarct size reduction in patients with anterior STEMI, if
reproduced in future adequately powered clinical trials will likely result
in significant improvement in clinical outcome. Stone et al, in a recent
pooled analysis of infarct size and clinical outcomes showed that for
every 5% decrease in absolute infarct size, there is a 20% reduction in
risk of hospitalization for heart failure or mortality.17
The results in this study reinforce the value of achieving sufficient
cooling prior to reperfusion, and support efforts to improve the
technology to cool faster and more effectively. To this end, the
recently reported COOL AMI EU pilot study, which used a more
powerful cooling system in patients with anterior STEMI, showed an
absolute 7% (relative 30%) decrease in infarct size in the per protocol
population, warranting the value in performing a fully powered
randomized control trial to confirm this signal.18
4.1 | Strengths and limitations
All of the studies used endovascular catheter cooling in the inferior
vena cava, and a similar strategy for controlling shivering. As opposed
to the use of a meta-analysis of aggregate data from published studies,
raw patient-level data was available from all of the clinical trials
included. Infarct sizewasmeasured by cMR and SPECT imaging in core
laboratories that were blinded to randomization assignment. Differ-
ences in methodology between SPECT and cMR may introduce
variability in the results. Despite the fact that cMR has higher spatial
resolution than SPECT, and is more sensitive in detecting small regions
of subendocardial infarction, prior studies have shown fairly compara-
ble infarct size results between the two modalities.19,20 Lund et al19
compared infarct size measurements with cMR and SPECT in 60
consecutive patients at 6 ± 3 days post intervention for STEMI. Mean
infarct size was not significantly different between cMR and SPECT
(20.7 ± 11.5% vs 19.4 ± 14.3%, P = 0.26). Hadamitzky et al20 evaluated
281 patientswith STEMI using cMRand SPECT amedian of 4.9 and 4.3
days after primary PCI. The difference between cMR and SPECT
(13.9 ± 11.5% vs 15.1 ± 17.2%, P = 0.35) was not significant when
using a quantitative threshold for infarction of four standard deviations
above remote myocardium for cMR, while the Pearson's correlation
coefficient r was 0.75. Further, infarct size measurements from 4 days
to 30 days post MI may introduce variability. A recent report of a
pooled analysis of infarct size by cMR (1889 patients) and SPECT (743
patients), concluded that infarct size measured by cMR or SPECT
within 1 month after primary PCI is strongly associated with all-cause
mortality and hospitalization for heart failure within 1 year.17 In this
pooled analysis, however, a significant reduction of infarct size in
patients cooled to <35°C persisted in spite of variability in the imaging
methodology.
The results were most positive in the anterior STEMI population.
Anterior infarcts are larger, and likely provide greater accuracy for
detecting changes due to treatment when measured by imaging
methodology such as SPECT or cMR.21 Further, patients presenting
with anterior infarction carry the highest mortality risk, risk for heart
failure post infarction, and are in the greatest need for timely
reperfusion and adjunctive cardioprotection against reperfusion
injury.22 Overall, the results support the need for larger RCTs in
patients with anterior STEMI using more powerful cooling devices to
optimize the ability of hypothermia to reduce infarct size.
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